EUROPA PASA DE TENER DOS TRATAMIENTOS SCLC-ES EN PRIMERA LINEA INMUNOTERAPIA ( ATEZOLIZUMAB
Y DURVALUMAB ) ... A TENER CUATRO ( ATEZOLIZUMAB, DURVALUMAB , SERPLULIMAB Y TISLELIZUMAB .
Dose Finding Clinical Trial With SYL040012 to Evaluate the Tolerability and Effect on Intraocular Pressure in Subjects With Ocular Hypertension or Open Angle Glaucoma .
...
Status : Recruiting Start date : 2012-07 Last follow-up date : 2013-12 (Anticipated) Primary completion date : 2013-05 (Anticipated)